A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525105-20-00

Enrollment

Registered

2026-07-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma (MM)

Brief summary

Dose Limiting Toxicities (DLT) of surzetoclax and etentamig in combination in biomarker-selected subjects with R/R MM.

Detailed description

Overall Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DOR), Time-to-Progression (TTP), Time to Next Treatment, Rate of minimal residual disease (MRD) Negativity Determined Centrally, using Adaptive's clonoSEQ NGS assay, Overall survival (OS), Pharmacokinetics (PK): Cmax, Tmax, t ½ , AUC.

Interventions

DRUGSurzetoclax

DRUGEtentamig

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Dose Limiting Toxicities (DLT) of surzetoclax and etentamig in combination in biomarker-selected subjects with R/R MM.	—

Secondary

Measure	Time frame
Overall Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DOR), Time-to-Progression (TTP), Time to Next Treatment, Rate of minimal residual disease (MRD) Negativity Determined Centrally, using Adaptive's clonoSEQ NGS assay, Overall survival (OS), Pharmacokinetics (PK): Cmax, Tmax, t ½ , AUC.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 15, 2026